By using its proprietary delNS technology, BlueSky Immunotherapies has created a viral vector platform for the induction of interferon and expression of tumor antigens. delNS vectors have many properties for overcoming the immunosuppressive environment of tumors. In the future, the delNS-based immunotherapy could be an effective alternative for humans when chemotherapy and surgical excision only have limited effects.
“The complete elimination of very aggressive and difficult-to-cure equine sarcoids is yet another important proof of the potential offered by our delNS platform. We are therefore confident that we will also be able to successfully heal and/or eliminate the cervical tumours of the women enrolled in the clinical trials currently under way,” explains Thomas Muster, CEO of BlueSky Immunotherapies.